Farmas USA

jod.. cambia la cara, que es para alegrarse. Eso si, hay que olvidar todo el recorrido anterior.

Por cierto, la carga institucional no ha aumentado en estos últimos meses, no?

ja,ja hay que olvidar todo el recorrido anterior ... SEGURO!

Institucionales mas o menos igual

AMRN

Hola compañeros.

ZGNX acaba de sobrepasar la resistencia de 1,70-1,71 que nos impedía avanzar. Sigue la tendencia claramente alcista (edit: desde finales de 2014). El 10 de Marzo ER (próximo martes).

Saludos!

Joer con las GERN...
Ayer cerré la posición asumiendo 140$ de pérdidas, aprox. un 10%...
Hoy he reentrado a 3,33, y veo que ya he recuperado lo perdido ayer....
A ver qué pasa mañanaaaaaaaaaaaaaa
Se trata de un rumor de compra por parte de Johnson...

Zaragozitaaaaaa que en unos dias te quitas de encima las ZGNX!!!!!!!

Que bueno!

un dia de estos me subire a esos trenes en marcha ... y seguro que descarrillo con todo el equipo ja,ja

Small cap Geron (GERN +17.8%) jumps on a 3x surge in volume as traders take positions speculating on the potential for a move by imetelstat collaboration partner and exclusive licensee Johnson & Johnson (JNJ +0.8%) after it was apparently outbid by AbbVie (ABBV -3.5%) for Pharmacyclics (PCYC +10.5%).SA Contributor Stock Doctor recently published an article on why Geron may be worth a close look.Previously: Geron wins deal to develop blood disorder drug, could get $935M (Nov. 13, 2014)

GERN

Imetelstat (IMET) is Already a Successful Drug; Geron & Janssen Biotech are Coming Together
No one questions the success of IMET. The medical successes are well documented, and the science has received a Nobel Prize. The telomere-telomerase interactions are a recognized building block in creating remissions and cures in blood cancers. IMET research is now moving forward into other types of cancer, including cancer stem cells. Mayo Clinic has been telling us that for awhile ("Tantamount to a Cure"), and Janssen/JNJ is the new home of Dr. Tefferi (the master of IMET), as Geron winds down, and Janssen becomes the major force in developing IMET, and setting up global trials.

Geron is still a public company, and will benefit from IMET's continuing successes as a safe, effective, and life saving cancer drug (alone and in combination). I believe that Geron will eventually become part of Janssen Biotech, but not before the PPS moves much higher. The final disposition of Geron, when it will happens, and the arrangements with Janssen are all matters of speculation.

http://online.barrons.com/articles/SB51367578116875004693704580500021807004844

Bajadita tonta de última hora, esta farma!!!
AMRN